Data / Drug companies / Genzyme Corporation
Genzyme Corporation: 33 products in the FDA NDC directory, labeler code 58468
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Genzyme Corporation (labeler code 58468) lists 33 products in the FDA National Drug Code Directory, covering 16 finished drugs by generic name. By type: 24 prescription drugs, 9 drugs for further processing. Its main marketing category is biologics (BLA). The newest product started marketing on August 29, 2025.
The request: Watch Genzyme Corporation (FDA labeler code 58468): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 58468
- Products in commercial distribution
- 33
- Packages
- 40
- Finished drugs by generic name
- 16
- Prescription products
- 24
- Over the counter products
- 0
- Flagged as original packager
- 21 of 21 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- May 23, 1994
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 13 | 39.4% |
| New drug applications (NDA) | 11 | 33.3% |
| Drugs for further processing | 9 | 27.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 24 | 72.7% |
| Drugs for further processing | 9 | 27.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Sevelamer carbonate | 3 | 35 |
| Fitusiran | 2 | 1 |
| Teriflunomide | 2 | 17 |
| Alemtuzumab | 2 | 1 |
| Vandetanib | 2 | 1 |
| Agalsidase beta | 2 | 1 |
| Olipudase alfa-rpcp | 2 | 1 |
| Thyrotropin alfa | 1 | 1 |
| Avalglucosidase alfa-ngpt | 1 | 1 |
| Rilzabrutinib | 1 | 1 |
| Anti-thymocyte globulin (rabbit) | 1 | 1 |
| Caplacizumab | 1 | 1 |
| Imiglucerase | 1 | 1 |
| Laronidase | 1 | 1 |
| Alglucosidase alfa | 1 | 1 |
| Eliglustat | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 12 | 36.4% |
| Tablet, film coated | 6 | 18.2% |
| Solution | 4 | 12.1% |
| Powder, for suspension | 2 | 6.1% |
| Injection, solution | 2 | 6.1% |
| Injection, powder, for solution | 2 | 6.1% |
| Injection, solution, concentrate | 2 | 6.1% |
| Injection | 1 | 3% |
| Kit | 1 | 3% |
| Capsule | 1 | 3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Phosphate Binder | 3 |
| Antithrombin-directed RNA Interaction | 2 |
| Small Interfering RNA | 2 |
| Pyrimidine Synthesis Inhibitor | 2 |
| CD52-directed Cytolytic Antibody | 2 |
| Hydrolytic Lysosomal Glycogen-specific Enzyme | 2 |
| Kinase Inhibitor | 2 |
| Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme | 2 |
| Thyroid Stimulating Hormone | 1 |
| Immunoglobulin G | 1 |
| Hydrolytic Lysosomal Glucocerebroside-specific Enzyme | 1 |
| Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme | 1 |
| Glucosylceramide Synthase Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Wayrilz | 58468-0251 | Tablet, film coated | New drug applications (NDA) | August 29, 2025 |
| Qfitlia | 58468-0348 | Injection, solution | New drug applications (NDA) | March 28, 2025 |
| Qfitlia | 58468-0347 | Injection, solution | New drug applications (NDA) | March 28, 2025 |
| Xenpozyme | 58468-0051 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 29, 2022 |
| Xenpozyme | 58468-0050 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 29, 2022 |
| Avalglucosidase alfa | 58468-5011 | Injection, powder, lyophilized, for solution | Drugs for further processing | August 6, 2021 |
| Nexviazyme | 58468-0426 | Injection, powder, lyophilized, for solution | Biologics (BLA) | August 6, 2021 |
| Avalglucosidase alfa | 58468-5006 | Solution | Drugs for further processing | June 8, 2021 |
| Dupilumab | 58468-5151 | Solution | Drugs for further processing | August 18, 2020 |
| Cablivi | 58468-0225 | Kit | Biologics (BLA) | February 6, 2019 |
| Dupilumab | 58468-5150 | Solution | Drugs for further processing | October 25, 2018 |
| Lemtrada | 58468-0200 | Injection, solution, concentrate | Biologics (BLA) | November 18, 2014 |
| Cerdelga | 58468-0220 | Capsule | New drug applications (NDA) | September 3, 2014 |
| Aubagio | 58468-0211 | Tablet, film coated | New drug applications (NDA) | May 1, 2013 |
| Aubagio | 58468-0210 | Tablet, film coated | New drug applications (NDA) | May 1, 2013 |
| Caprelsa | 58468-7840 | Tablet, film coated | New drug applications (NDA) | July 25, 2011 |
| Caprelsa | 58468-7820 | Tablet, film coated | New drug applications (NDA) | July 25, 2011 |
| Lumizyme | 58468-0160 | Injection, powder, for solution | Biologics (BLA) | May 24, 2010 |
| Campath | 58468-0357 | Injection | Biologics (BLA) | November 30, 2009 |
| Renvela | 58468-0133 | Tablet, film coated | New drug applications (NDA) | August 12, 2009 |
| Renvela | 58468-0132 | Powder, for suspension | New drug applications (NDA) | August 12, 2009 |
| Renvela | 58468-0131 | Powder, for suspension | New drug applications (NDA) | August 12, 2009 |
| Fabrazyme | 58468-0041 | Injection, powder, lyophilized, for solution | Biologics (BLA) | December 17, 2008 |
| Fabrazyme | 58468-0040 | Injection, powder, lyophilized, for solution | Biologics (BLA) | December 17, 2008 |
| Alglucosidase alfa | 58468-5005 | Solution | Drugs for further processing | April 28, 2006 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.